FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
+7.69%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$345M
AUM Growth
+$345M
(-13%)
Cap. Flow
-$51.5M
Cap. Flow
% of AUM
-14.92%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
1
Top Buys
No buys this quarter
Top Sells
| 1 |
Editas Medicine
EDIT
|
$51.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Denali Therapeutics
DNLI
$2.26B
| $176M | 50.92% |
8,918,749
| – | – |
|
2
Seres Therapeutics
MCRB
$171M
| $93.1M | 26.99% |
12,682,876
| – | – |
|
|
SYRS
3
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $41.6M | 12.06% |
3,204,437
| – | – |
|
4
Quanterix
QTRX
$209M
| $34.6M | 10.03% |
2,030,495
| – | – |
|
|
5
Editas Medicine
EDIT
$222M
| – | – |
-1,674,435
| Closed | -$51.5M |
|